21 CFR Part 814 Premarket Approval

Premarket Approval, or PMA, is the FDA's most rigorous review pathway for Class III medical devices. It requires valid scientific evidence demonstrating reasonable assurance of safety and effectiveness for the device's intended use. A PMA typically includes clinical data, device description, manufacturing information, labeling, nonclinical testing, and detailed quality documentation reviewed under 21 CFR Part 814.

21 CFR refers to Title 21 of the Code of Federal Regulations, which contains FDA regulations for products such as medical devices, drugs, and biologics. For device manufacturers, relevant parts often include Part 814 for PMA, Part 820 for quality systems, Part 803 for medical device reporting, and Part 801 for labeling. The exact requirements depend on device type and regulatory pathway.

PMA is generally required for Class III medical devices, especially those that support or sustain human life, are implanted, or present a potentially unreasonable risk of illness or injury. These devices usually cannot rely on substantial equivalence like a 510(k). FDA classification regulations, product codes, and prior agency feedback help determine whether PMA is the correct pathway.

A PMA submission typically includes administrative information, device description, indications for use, nonclinical testing, clinical investigation data when required, manufacturing methods and controls, labeling, summaries of safety and effectiveness, and supporting bibliographic references. FDA expects the submission to be internally consistent, scientifically justified, and traceable across technical, clinical, and quality documentation.

A 510(k) is based on demonstrating substantial equivalence to a legally marketed predicate device, while a PMA requires independent evidence showing safety and effectiveness. PMA is more data-intensive, often involves clinical evidence, and receives deeper FDA review. It is typically used for higher-risk Class III devices, whereas many Class II devices follow the 510(k) pathway.

Yes. FDA commonly issues deficiency letters or additional information requests when sections are incomplete, inconsistent, or unsupported by adequate evidence. These questions may address clinical data, manufacturing controls, biocompatibility, software, labeling, or risk management. Well-prepared responses should directly answer each point, include supporting references, and maintain consistency across the full submission package.

A submission readiness assessment helps identify weaknesses before they become formal FDA deficiencies. It reviews whether technical documentation, clinical evidence, risk files, labeling, and quality system records are complete and aligned with the expected PMA standard. This allows manufacturers to prioritize remediation, improve submission quality, and avoid delays caused by preventable gaps or contradictory evidence.

Not every change is handled the same way, but many significant changes to a PMA-approved device require FDA notification or a PMA supplement. The impact of changes to design, manufacturing, software, labeling, or intended use must be assessed carefully. A documented change impact assessment helps determine the appropriate regulatory action and creates an auditable rationale for the decision.